Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 468-471

  Sandlund, J T ^a,b   Pui, C H ^a,b   Mahmoud, H ^a,b   Zhou, Y ^a   Lowe, E ^a   Kaste, S ^a,b   Kun, L E ^a   Krasin, M J ^a   Onciu, M ^a   Behm, F G ^a   Ribeiro, R C ^a,b   Razzouk, B I ^a,b   Howard, S C ^a,b   Metzger, M L ^a,b   Hale, G A ^a,b   Rencher, R ^a   Graham, K ^a   Hudson, M M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Childhood; Lymphoma; Recurrent; Refractory

Indexed keywords

DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE;

ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 79251565546     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq348     Document Type: Article

References (16)

1. Reiter A, Schrappe M, Ludwig WD et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95(2): 416-421.
2. Reiter A, Schrappe M, Tiemann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94(10): 3294-3306.
3. Seidemann K, Tiemann M, Schrappe M et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97(12): 3699-3706.
4. Laver JH, Kraveka JM, Hutchison RE et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005; 23(3): 541-547.
5. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334(19): 1238-1248.
6. Cairo MS, Gerrard M, Sposto R et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109(7): 2736-2743.
7. Patte C, Auperin A, Gerrard M et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109(7): 2773-2780.
8. Schellong G, Dorffel W, Claviez A et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23(25): 6181-6189.
9. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97(3): 616-623.
10. Kobrinsky NL, Sposto R, Shah NR et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19(9): 2390-2396.
11. Santana VM, Abromowitch M, Sandlund JT et al. MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma. Leukemia 1993; 7(2): 187-191.
12. Kung FH, Harris MB, Krischer JP. Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study. Med Pediatr Oncol 1999; 32(3): 225-226.
13. Brugieres L, Quartier P, Le Deley MC et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol 2000; 11(1): 53-58.
14. Sandlund JT, Pui CH, Santana VM et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994; 12(5): 895-898.
15. Gordon BG, Warkentin PI, Weisenburger DD et al. Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. Blood 1992; 80(11): 2938-2942.
16. Woessmann W, Peters C, Lenhard M et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Munster group report. Br J Haematol 2006; 133(2): 176-182.